NCT04129411Completed
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
Pilot Study for the Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
Source: ClinicalTrials.gov · Last updated 20 May 2025
Brief summary (registry, in English)
Investigators intend to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to treat papillary thyroid carcinoma.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 5 (actual)
- First submitted
- 4 Oct 2019
- Start date
- 15 Jun 2020
- Primary completion date
- 7 May 2024
- Lead sponsor
- Mayo Clinic
- Diseases
- Thyroid cancer
- NCT number
- NCT04129411
What you commit to
- Study type: Interventional
- Participants enrolled: 5
- From 15 Jun 2020 to the primary completion date, 7 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Coagulopathy or patients on anticoagulation therapy
- Patients with prior neck surgery or neck radiation
- Treatment with another investigational drug or intervention (within 6 weeks of planned RFA).
- Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
Other illness
- Clinical evidence for a multifocal papillary thyroid malignancy
- Clinical evidence for local or distant metastatic disease
Other
- Pregnancy
- Vocal cord paralysis on contralateral side
- Patients with neck anatomy that precludes easy access by RFA
- Patients with comorbidities deemed too high of a risk for general anesthesia
Who the study is looking for
- Are adults
- Nodule with Papillary thyroid carcinoma meeting the below criteria:
- Diagnosed by fine needle aspiration (FNA) cytology.
- Size \< 1.5 cm
- Non-surgical therapy is considered acceptable by the treating physician
- Radiology evaluation deems the lesion amenable to RFA therapy with minimal risk of complication
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.